Hey readers! This week's issue has a mouse doing something no celiac mouse has done before: matching a human clinical trial, molecule for molecule. That is a bigger deal for drug development than it sounds, so let's start there, then walk through the actual celiac drug pipeline you can follow (ANB033, TEV-'408), a rethink of what gluten does to your immune system, gut-bacteria clues, and a parenting story a lot of you will recognize.
🐭 A better mouse for testing celiac drugs
Humanized mouse model could significantly improve preclinical testing of celiac drugs reports on work from the Institute for Translational Immunology led by Dr. Detlef Schuppan, who engineered the human antigen-presenting molecule HLA-DQ8 into the mouse genome so the animal reacts to gluten more like a person with celiac genetics does. - Medical Xpress
Why this matters: celiac drug programs have struggled because promising compounds looked good in the lab and then fizzled in people. The team validated the model with ZED1227, a transglutaminase 2 inhibitor that in a 2021 phase 2a trial of 160 patients protected the intestinal mucosa from gluten damage. In the humanized mice, ZED1227 produced the same story: largely preserved villi, less inflammation, and molecular immune changes that matched the clinical data.
"For the first time, it gives us the opportunity to investigate new active compounds in a mouse model and directly compare the results with data from clinical trials. In addition, the molecular mechanisms of promising active compounds could be better investigated even before clinical trials."
A model that lines up with human trial results means researchers can screen candidates and study mechanisms before spending years and dollars on people who may not benefit. For anyone waiting on a real celiac drug, faster and smarter preclinical filtering is exactly what the field has been missing.
💊 The celiac drug pipeline worth watching
Speaking of drugs in humans, two programs are moving right now and both are worth bookmarking.
First Tracks Biotherapeutics Q2 2026 update says its CD122 antagonist ANB033 has completed Cohort 1 (gluten challenge) enrollment in the Phase 1b celiac trial, with top-line data reaffirmed for Q4 2026 and Cohort 2 (mucosal healing) data expected in Q1 2027. - Shelby Daily Globe
The FDA granted ANB033 Fast Track designation for celiac disease in people already on a gluten-free diet, which the company frames as recognition of the unmet need for those who stay symptomatic despite eating clean.
"In celiac disease, FDA's Fast Track designation for ANB033 underscores both the urgency of the significant unmet need for patients and the potential of this program."
Teva Advances TEV-'408 Into Phase 2b for Vitiligo is mostly a skin-disease story, but buried in it is celiac news: TEV-'408, an anti-IL-15 monoclonal antibody, is in Phase 2a evaluation for celiac disease and got FDA fast track for that indication in 2025. - Dermatology Times
The interesting angle is the biology. Anti-IL-15 aims to interrupt tissue-resident memory T cells, the cells that keep an autoimmune response smoldering. If that mechanism holds up, it could matter for celiac patients whose guts stay inflamed even after gluten leaves the picture. One dermatologist's take on the modality:
"Given that every patient may not be an optimal candidate for a JAK inhibitor based on safety, tolerability, preference, or even efficacy, having multiple options with alternate modes of action is critical."
A quick note for anyone eyeing biotech news through an investor lens: a separate TRAX SWOT analysis flags that First Tracks is operating at a loss with a GF Score of 12/100, even after an $80 million private placement. Promising pipeline, thin finances. Worth keeping in perspective as timelines slip or hold.
🔬 Rethinking what gluten does to your immune system
Study Suggests a Potential New Cause of Celiac Disease covers research in Immunology and Cell Biology finding that CD4 helper T cells in celiac patients actually showed reduced activity early on: less interleukin-2, slower division, lower survival, regardless of sex, how recently they were diagnosed, or how long they had been gluten-free. - The Epoch Times
The researchers describe a concept they call "immune momentum," observed using Cyton2 Cell Timer technology and a signal-removal assay. The implication is that celiac may reflect a baseline difference in immune wiring, not just an overreaction to gluten. That ties back nicely to the humanized mouse work above, since a model built on human HLA genetics is exactly the tool you would want to probe this kind of inherited susceptibility.
"They may reflect a built-in immune tendency, likely influenced by genetics."
Careful reading required, though. The same experts stress this is early and want larger, long-term studies before anyone uses immune-cell testing for earlier detection.
On the dosing side, Should the Gluten Threshold Dose in Celiac Disease Change Based on Immune Activation? covers a randomized trial measuring IL-2 responses to gluten challenges from 1 to 1000 mg in 51 adults. Immune activation showed up at doses below current gluten-free labeling limits, but the editorialist cautions that symptoms did not track IL-2 below 1 g and that longer studies are needed before rewriting labeling rules. - gutsandgrowth
🦠 Gut bacteria clues, before symptoms even start
New research finds gut bacteria connection to celiac disease describes a meta-analysis that identified a consistent microbiome "signature" across healthy people, those at pre-disease onset, and people with active disease, using machine learning to sift through global cohorts. - Massey University
Healthy individuals carried more fibre-loving, butyrate-producing bacteria and protective metabolites, while celiac disease was linked to increased pathogenic Bacteroides species and depletion of protective ones. The striking part is timing:
"It gives us evidence that changes are happening in the gut before disease is occurring."
Coeliac disease: Canterbury research finds gut bacteria changes before disease develops covers the companion Riddet Institute work in Canterbury children, which found the same shifts persisted even on a gluten-free diet. - NZ Herald
That last point deserves attention: since a gluten-free diet can cut fibre intake, it may quietly nudge the gut away from those protective butyrate producers. The researchers float fibre and beneficial-microbe restoration as future prevention ideas, though this is still a research direction, not a treatment.
🩺 Diagnosis, families, and everyday life
A few items that round out the picture for practitioners and families:
Update of the Protocol for the Early Diagnosis of Coeliac Disease - Spain's updated early-diagnosis protocol, developed under the GuiaSalud program with 13 scientific societies, covers diagnosis through refractory disease and complications. A useful reference given how underdiagnosed celiac remains.
Could Up to 85% of Americans With Celiac Disease Still Be Undiagnosed? - A 129-million-record study found only about 0.16% with a recorded diagnosis, but Celiac.com is refreshingly honest that this arithmetic is a warning sign, not proof, since the study searched codes rather than screening people.
Impact of breastfeeding on serological recovery in postpartum women with celiac disease - In 255 women, exclusive breastfeeding was tied to higher serological remission at 12 months (92% vs 74%), faster tTG-IgA decline, and better ferritin and bone scores.
Small-fibre neuropathy in coeliac disease - In 36 adults, neuropathic symptoms lined up with small-fibre pathology rather than sensorimotor nerve damage; the authors suggest considering SFN in the work-up of nerve complaints.
Dylan Dreyer reveals 'unfair' part of son Calvin's celiac diagnosis is the story a lot of parents will feel in their bones. After Calvin's 2023 diagnosis, the family went fully gluten-free and tossed anything that could harbor gluten. - Hello Magazine
"All of my stuff in the kitchen had to be thrown out, all of our wooden spoons, wooden cutting boards, anything that had a scratch in it ... All of that had to be thrown out because gluten can hide everywhere."
Her frustration with limited, pricey gluten-free options is real, and it's a good reminder of how much daily logistics shape life with celiac. On that note, a genuinely handy tool for finding safe food, restaurants, and travel options is Find Me Gluten Free (findmeglutenfree.com) and its app. We're not sponsored by them; it's just useful when you're navigating an unfamiliar grocery aisle or a menu on the road.
That's the issue. A mouse that finally matches human trials, two drug programs with hard dates to watch, and a growing sense that celiac starts wiring itself long before the first bite of bread. See you next time.